TransMedics Group, Inc. (TMDX) is a groundbreaking medical technology company that is revolutionizing organ transplant therapy. The company is based in Andover, Massachusetts. The mission of TransMedics Group is to overcome the limitations of conventional organ storage and strengthen the bridge between organ donation and transplantation, transforming it into a seamless process by preserving the quality and functionality of donated organs.
The company's keen foresight and progressive innovation led to the development of their Organ Care System (OCS), also known as the 'Organ in a Box.' This revolutionary technology has the capacity to optimize the quality of organs before transplantation by maintaining the conditions necessary for organs to function, thereby extending the period of organ viability. This approach potentially broadens donor criteria and increases organ utilization, augmenting life-saving transplantation opportunities.
TransMedics Group, Inc.'s approach to organ preservation and transplantation is transformative to the organ transplant industry. Traditional preservation methods involved storing organs in cold static conditions which could lead to organ degradation and limited transportation time. TransMedics' OCS, in contrast, infuses donated organs with a blood-based preservation solution, supplied with oxygen, balanced concentrations of metabolic substrates, and electrolytes. That way, the organ is kept in a warm, functioning state between the time of donation and transplantation, maintaining optimal functionality.
The company was founded in the year 1998 by Dr. Waleed Hassanein, who aimed to overcome the historical limitations of cold static storage of donated organs. Heavily investing in research and development, the company has continually introduced pioneering solutions aimed at transforming organ transplant.
TransMedics Group, Inc. has been determined to expand OCS's global availability and its application across other solid organs. As per its Q2 2021 investor presentation, the company reported revenue of $9.2 million and is currently focusing on market penetration and adoption of its products. At present, TransMedics is striving to become the worldwide standard of care for organ preservation and transplantation.
Serving the noble cause of organ transplantation and contributing to saving countless lives, TransMedics Group, Inc. stands at the forefront of significant change within the medical world. Their uncompromising dedication to improving organ transplantation therapies, their commitment to innovation, and their dedication to expanding the capabilities of their OCS technology paint a promising future for the company and the organ transplant industry as a whole. With consistent growth, ground-breaking products, and unyielding perseverance, TransMedics Group, Inc. remains a strong presence in today's healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
UBS Group raised its price target for TransMedics Group (NASDAQ:TMDX) to $88.00 from $77.00, while maintaining a "neutral" rating. This new target implies a potential downside of 6.19% from the stock's previous close. The medical technology company recently reported strong quarterly earnings, beating analyst estimates with an EPS of $0.51 and revenue of $203.01 million, representing a 41.1% year-over-year increase.
JPMorgan Chase & Co. raised its price target for TransMedics Group (NASDAQ:TMDX) stock from $73.00 to $85.00, while maintaining a "neutral" rating. Despite the upgrade, the new target implies a potential downside of 3.67% from the company's previous close. The company recently surpassed quarterly earnings expectations, reporting EPS of $0.51 and revenue of $203.01 million, significantly exceeding analyst estimates.
Wall Street Zen upgraded TransMedics Group (NASDAQ:TMDX) from a "sell" to a "hold" rating. The company reported strong third-quarter results, beating analyst estimates with $203.0 million in revenue and $0.51 EPS, and raised its 2026 revenue outlook. Despite these positive financial indicators, some key catalysts have been delayed to early 2027.
Needham & Company LLC has raised its price target for TransMedics Group (NASDAQ:TMDX) to $110.00, maintaining a "buy" rating. This adjustment comes after TransMedics reported strong quarterly revenue of $203 million, a 41.1% increase year-over-year, and an EPS of $0.51, surpassing analyst estimates. The company also increased its 2026 revenue guidance, reflecting confidence in its continued growth, despite a slight decline in EPS from the previous year.
TransMedics Group reported strong Q3 2026 revenue of US$203.01 million and raised its full-year revenue guidance, driven by record case volumes and increased adoption of its organ care and logistics platform. Despite a decline in industry donor volumes, the company's expanded Liver and Heart offerings, along with its logistics network, suggest it is capturing a larger market share. While sales are up, net income was lower year-over-year, indicating a focus on execution and cost discipline will be key to converting current spending into stable earnings.
TransMedics (TMDX) reported record Q3 2026 revenue of $203 million, a 41% year-over-year increase, driven by strong growth in Liver and Heart OCS case volumes and market share gains despite a decline in overall U.S. disease donor volume. The company raised its full-year 2026 revenue guidance to $764 million to $774 million and highlighted progress in its ENHANCE Heart Part A and Part B trials, DENOVO Lung program, OCS Kidney development, and expansion of its NOP services and transplant logistics network into Europe, including winning its first European tender in Italy.
TransMedics Group (NASDAQ:TMDX) announced strong quarterly earnings, beating analyst expectations with an EPS of $0.51 against a consensus of $0.30, and revenue reaching a record $203.01 million. The company raised its 2026 revenue guidance to $764 million–$774 million, driven by increased organ transplantation volumes and new growth opportunities in heart and lung programs. Despite a slight decline in gross margin due to a larger share of lower-margin services, management expressed a conservative but optimistic outlook for the fourth quarter.